GIANT CELL TUMOR OF THE PATELLA:

The Complete Imaging Guide from X-ray to MRI, CT, AI Diagnosis and Modern Treatment

Introduction

Persistent anterior knee pain is among the most common musculoskeletal complaints encountered in orthopedic clinics and radiology departments. In the majority of patients, the underlying diagnosis involves relatively benign conditions such as patellofemoral pain syndrome, chondromalacia patellae, tendinopathy, or early osteoarthritis. Because these disorders are exceedingly common, clinicians may initially attribute chronic anterior knee pain to overuse or degenerative disease.

However, every radiologist eventually encounters the uncommon patient whose symptoms are caused not by a mechanical disorder but by an underlying bone tumor.

Among primary tumors involving the patella, Giant Cell Tumor (GCT) deserves special attention because it represents the most frequent primary neoplasm of the patella despite the overall rarity of patellar tumors. The lesion is histologically benign but biologically aggressive, with a propensity for cortical destruction, soft-tissue extension, local recurrence, and, in rare cases, pulmonary metastasis. Failure to recognize the imaging characteristics may delay diagnosis, resulting in progressive bone destruction and more extensive surgery. These source-derived points are emphasized throughout the attached case study.

The present case involves a 35-year-old woman who presented with progressively worsening anterior knee pain over approximately one year. Clinical examination demonstrated difficulty climbing stairs, decreased quadriceps strength, and impaired active knee extension—findings that raised suspicion for a primary patellar lesion rather than a simple overuse syndrome. Subsequent imaging with radiography, MRI, CT, and CT-guided biopsy established the diagnosis of a giant cell tumor of the patella, followed by treatment with Denosumab and surgery.

This case highlights why radiologists should maintain a high index of suspicion whenever imaging reveals an expansile osteolytic lesion involving the patella. Early identification affects not only diagnostic accuracy but also surgical planning, preservation of the extensor mechanism, and long-term functional outcomes.

Clinical Case Story

A 35-year-old woman sought medical evaluation because of persistent left anterior knee pain that had gradually worsened over the preceding year. Initially, the pain was intermittent and activity-related, especially while climbing stairs. Over time, it became more constant, accompanied by reduced extension strength and functional limitation of the affected knee. These findings suggested that the pathology originated within the patella itself rather than from periarticular soft tissues.

Routine radiographs revealed a striking expansile osteolytic lesion occupying nearly the entire patella. Rather than demonstrating aggressive periosteal reaction or mineralized tumor matrix, the lesion showed cortical thinning with fine internal septations. This radiographic appearance immediately narrowed the differential diagnosis and prompted further cross-sectional imaging.

MRI demonstrated replacement of almost the entire patella by tumor tissue with heterogeneous enhancement, central necrosis, and extension into adjacent soft tissues including the suprapatellar pouch, infrapatellar fat pad, and prepatellar soft tissues. CT further confirmed cortical breakthrough without evidence of mineralized matrix and also assisted in planning CT-guided biopsy.

Histopathologic confirmation preceded treatment. According to the attached case, neoadjuvant Denosumab therapy was administered before curettage and bone grafting. During follow-up, local recurrence was detected after one year, and maintenance Denosumab therapy resulted in disease stabilization.

Clinical Background

Giant Cell Tumor of Bone (GCTB) is a locally aggressive primary bone neoplasm characterized by osteoclast-like multinucleated giant cells and neoplastic mononuclear stromal cells. Although histologically benign, it behaves in an aggressive fashion, producing progressive bone destruction and occasionally extending into adjacent soft tissues. The attached document also notes that local recurrence and, more rarely, pulmonary metastasis may occur despite its benign classification.

From an epidemiologic standpoint, the source material reports that giant cell tumor accounts for approximately 5% of primary bone tumors and 20% of benign bone tumors, occurring most commonly in adults between 20 and 40 years of age. The knee region is the most frequent anatomic site overall, while involvement of the patella is uncommon but represents the most frequent tumor arising in that bone.

The biologic behavior of GCT is closely linked to activation of the RANK/RANKL signaling pathway, which promotes osteoclast recruitment and bone resorption. This molecular mechanism provides the rationale for treatment with Denosumab, a monoclonal antibody targeting RANKL, as described in the attached case.

Clinically, patients often present with persistent anterior knee pain, swelling, reduced range of motion, and diminished extension strength. If diagnosis is delayed, the lesion may enlarge sufficiently to cause cortical destruction, pathologic fracture, impaired gait, and significant loss of knee function.

Imaging Findings

The diagnosis of Giant Cell Tumor of the Patella (GCTP) is fundamentally an imaging diagnosis supported by histopathology. While biopsy provides definitive confirmation, radiologists frequently establish a highly confident pre-biopsy diagnosis through the combined interpretation of radiographs, MRI, and CT findings.

This case demonstrates the classic imaging progression used in musculoskeletal oncology:

The attached case is an excellent example of this workflow.

Figure 1. Standing AP Radiograph

Radiologic Interpretation

The standing AP radiograph demonstrates:

Expansile osteolytic lesion
Near-complete involvement of the patella
Marked cortical thinning
Fine internal septations
Absence of periosteal reaction

These findings represent the classic radiographic appearance of giant cell tumor. The lesion appears geographically destructive while maintaining relatively well-defined margins.

The absence of aggressive periosteal reaction is particularly important because it argues against many high-grade malignant bone tumors.

Source-derived key features include:

Expansile osteolytic lesion
Thin cortex
Fine septations
No periosteal reaction

Figure 2. Lateral Knee Radiograph

Radiologic Interpretation

The lateral projection provides additional evaluation of:

Longitudinal tumor extent
Cortical preservation
Anterior and posterior expansion

In this case, the lesion essentially replaces the normal cancellous architecture of the patella.

Important observations include:

Loss of normal trabecular pattern
Extensive bone replacement
Diffuse cortical thinning
Patellar enlargement

These findings suggest a slowly progressive but biologically aggressive process.

Figure 3. Skyline View

Why the Skyline View Matters

Many radiologists underestimate the value of the skyline projection.

For patellar tumors, this view often provides the clearest demonstration of:

Internal architecture
Fine septations
Degree of expansion
Relationship to articular surfaces

In the present case, fine septations become especially conspicuous on the skyline view, supporting the diagnosis of giant cell tumor.

The Four Radiographic Clues Every Radiologist Should Recognize

When evaluating a patellar lesion, the following combination should immediately raise concern for giant cell tumor:

1. Expansile Osteolytic Lesion

The lesion expands the bone rather than infiltrating diffusely.

2. Cortical Thinning

Tumor growth gradually erodes the cortex.

3. No Periosteal Reaction

Despite aggressive local behavior, periosteal reaction is typically absent.

4. Fine Internal Septations

Residual trabeculae create a multiloculated appearance.

The source document specifically highlights this four-feature combination as highly suggestive of GCT.

Why MRI Changes Everything

Radiographs reveal the lesion.

MRI reveals the true disease burden.

For musculoskeletal oncologists and radiologists, MRI is the most important modality for:

Determining tumor extent
Evaluating soft tissue invasion
Assessing surgical margins
Detecting necrosis
Characterizing synovial involvement

The attached case emphasizes that MRI revealed substantially greater disease extent than was appreciated on radiographs alone.

Figure 4. Axial MRI

Radiologic Interpretation

Axial MRI demonstrates a large expansile mass replacing nearly the entire patella.

Signal characteristics include:

T1-weighted Imaging

Low to intermediate signal intensity

T2-weighted Imaging

Predominantly high signal intensity

Post-Contrast Imaging

Heterogeneous enhancement
Non-enhancing central necrotic component

MRI further demonstrates extension into:

Suprapatellar pouch
Infrapatellar fat pad
Prepatellar soft tissues

These findings strongly indicate aggressive local behavior.

Figure 5. Sagittal MRI

Radiologic Interpretation

Sagittal MRI provides a comprehensive assessment of:

Superior-inferior tumor extent
Cortical integrity
Articular relationships

Key findings include:

Near-total replacement of the patella
Severe cortical thinning
Suspected cortical breakthrough
Small cystic component
Synovial thickening
Synovial enhancement

Importantly, no classic fluid-fluid levels are identified.

This finding argues against aneurysmal bone cyst as the primary diagnosis.

MRI Features That Predict Aggressive Disease

Musculoskeletal radiologists should carefully evaluate:

Tumor Occupancy

Does the lesion involve the entire patella?

Cortical Destruction

Has cortical breakthrough occurred?

Soft Tissue Extension

Has the tumor escaped the bone?

Necrosis

Are non-enhancing components present?

Pathologic Fracture Risk

Is the cortex sufficiently weakened?

Synovial Involvement

Has the adjacent joint become involved?

These parameters directly influence surgical planning.

Figure 6. CT Bone Window

Radiologic Interpretation

Bone-window CT remains the gold standard for evaluating cortical integrity.

The lesion demonstrates:

Expansile osteolytic destruction
Homogeneous soft tissue density
Severe cortical thinning
Cortical breakthrough

Perhaps most importantly:

No Mineralized Matrix

No osteoid matrix is identified.

No chondroid calcification is identified.

This observation helps exclude osteosarcoma and chondroid tumors.

Figure 7. CT Soft Tissue Window

Radiologic Interpretation

Soft tissue window imaging better defines:

Extraosseous extension
Biopsy approach
Relationship to surrounding structures

The lesion demonstrates:

Homogeneous attenuation
Soft tissue density
Extension beyond cortical confines

The source document notes that CT also provided critical information for CT-guided biopsy planning.

Imaging Summary Table

Modality	Key Findings
X-ray	Expansile osteolytic lesion, cortical thinning, septations, no periosteal reaction
MRI	T1 low-intermediate signal, T2 high signal, soft tissue extension, necrosis
CT	Cortical breakthrough, no mineralized matrix, homogeneous soft tissue density

This summary reflects the imaging findings reported in the attached case.

Differential Diagnosis

Even when imaging strongly suggests giant cell tumor, differential diagnosis remains essential.

The attached document lists the following entities.

Benign Lesions

Giant Cell Tumor
Chondroblastoma
Chondroma
Aneurysmal Bone Cyst
Simple Bone Cyst
Osteoid Osteoma
Osteoblastoma
Osteochondroma
Hemangioma
Ganglion

Malignant Lesions

Metastasis
Osteosarcoma
Lymphoma
Hemangioendothelioma
Malignant Fibrous Histiocytoma
Plasmacytoma
Angiosarcoma

Radiologist's Diagnostic Checklist

When evaluating a patellar tumor, experts should systematically ask:

Does the lesion involve the entire patella?
Is mineralized matrix present?
Is cortical integrity preserved?
Is there soft tissue extension?
Is necrosis present?
Should biopsy precede surgery?

The source case emphasizes these exact questions as practical radiologic decision points.

AI Applications in Musculoskeletal Tumor Imaging

The rise of AI is rapidly changing how radiologists approach bone tumor assessment.

Potential applications include:

Deep Learning Detection

Automated recognition of:

Osteolytic lesions
Cortical breakthrough
Tumor margins
Pathologic fracture risk

Computer Vision

AI algorithms can identify subtle imaging patterns that may be overlooked during routine interpretation.

Radiomics

Extraction of hundreds of quantitative imaging biomarkers from CT and MRI.

Foundation Models

Large multimodal healthcare models may soon integrate:

Imaging
Pathology
Clinical history
Genomics

to generate comprehensive diagnostic recommendations.

Clinical Decision Support Systems

Such systems are particularly attractive for rare tumors like patellar GCT because many clinicians encounter only a handful of cases during their careers.

Figure Suggestion

Future AI-Enhanced Radiology Workflow

Treatment Strategy

Although Giant Cell Tumor of Bone (GCTB) is classified as a benign neoplasm, its biologic behavior is distinctly aggressive. Therefore, treatment aims not only to eradicate the tumor but also to preserve knee function, minimize recurrence, and maintain long-term quality of life. The attached case emphasizes these four therapeutic goals, particularly because the patella is a key component of the knee extensor mechanism.

Why Biopsy Must Precede Definitive Treatment

Radiologic findings may strongly suggest giant cell tumor; however, imaging alone cannot reliably exclude other aggressive lesions.

The attached case therefore followed the standard sequence:

This approach avoids inappropriate surgery for lesions such as:

Chondroblastoma
Osteosarcoma
Lymphoma
Metastasis
Aneurysmal Bone Cyst

The source explicitly notes that CT-guided biopsy was performed before treatment because these entities must be excluded histologically.

Modern Role of Denosumab

One of the most significant advances in the management of giant cell tumor has been the introduction of Denosumab, a monoclonal antibody targeting the RANKL pathway. The attached document identifies RANK/RANKL signaling as central to GCT pathophysiology and explains why Denosumab is effective in this setting.

Clinical Objectives of Neoadjuvant Denosumab

Reduce tumor activity
Promote peripheral bone formation
Facilitate less extensive surgery
Improve preservation of the extensor mechanism
Decrease intraoperative morbidity

In the presented case, Denosumab was administered before surgery, followed by curettage and bone grafting. During follow-up, local recurrence developed after one year, and maintenance Denosumab therapy achieved stable disease.

Surgical Management

The source outlines three principal surgical strategies.

1. Curettage

Advantages

Patellar preservation
Better postoperative function
Faster rehabilitation

Limitations

Higher local recurrence risk

The attached material reports recurrence rates of 21–65% after curettage alone.

2. Curettage with Adjuvant Therapy

Adjunctive treatments include:

Bone cement
Thermal treatment
Chemical adjuvants

According to the source, these measures reduce recurrence to approximately 6–25%.

3. Patellectomy

Patellectomy is reserved for advanced disease with:

Extensive soft-tissue invasion
Pathologic fracture
Inability to preserve the patella

Because removal of the patella substantially affects knee biomechanics, the attached document recommends preservation whenever feasible.

Prognosis

Although giant cell tumor is histologically benign, prognosis depends on several clinical and imaging factors.

The source identifies the following major prognostic indicators:

Completeness of tumor removal
Soft-tissue extension
Presence of pathologic fracture
Local recurrence
Pulmonary metastasis

Long-term surveillance is recommended because recurrence may occur even after apparently successful treatment.

What Happens When Diagnosis Is Delayed?

The attached case emphasizes that prolonged anterior knee pain should not automatically be attributed to degenerative disease. Delayed diagnosis may lead to:

Progressive patellar destruction
Pathologic fracture
More extensive surgery
Permanent loss of knee function
Repeat operations
Rare pulmonary metastasis

The source concludes that persistent anterior knee pain with an osteolytic patellar lesion on radiographs should prompt MRI evaluation and tissue diagnosis.

AI Applications in Musculoskeletal Oncology

Beyond this individual case, AI has the potential to improve multiple stages of bone tumor management.

Deep Learning

Automated detection of osteolytic lesions
Cortical breakthrough recognition
Tumor segmentation

Computer Vision

Recognition of subtle radiographic patterns
Identification of soft-tissue extension
Quantitative assessment of lesion size

Radiomics

Extraction of quantitative CT and MRI features
Correlation with recurrence risk
Prediction of treatment response

Foundation Models

Future multimodal systems may combine:

Imaging
Clinical history
Pathology
Genomics

to assist radiologists and orthopedic oncologists in complex decision-making.

Enterprise Clinical Decision Support

Such enterprise workflows may improve consistency and efficiency, especially for rare tumors that individual clinicians encounter infrequently.

Key Imaging Pearls

Based on the attached case, the following imaging features are particularly important for radiologists.

Persistent anterior knee pain warrants imaging evaluation.
Giant cell tumor is the most common primary tumor of the patella despite its rarity.
Expansile osteolytic destruction is the hallmark radiographic finding.
Cortical thinning without periosteal reaction strongly favors GCT.
Fine internal septations are a valuable diagnostic clue.
MRI is the best modality for evaluating soft-tissue extension.
CT most accurately demonstrates cortical breakthrough.
Absence of mineralized matrix argues against osteosarcoma or chondroid tumors.
CT-guided biopsy should precede definitive treatment in aggressive lesions.
Long-term imaging follow-up is essential because local recurrence can occur.

Future Perspectives

Over the next 5–10 years, musculoskeletal oncology is expected to benefit from:

AI-assisted lesion detection
Automated radiology reporting
Multimodal foundation models
Radiomics-guided risk prediction
Digital pathology integration
Cloud-based enterprise imaging platforms
Personalized treatment planning
Predictive recurrence modeling

These developments represent broader trends in AI-enabled medical imaging rather than findings specific to the attached case.

Key Takeaways

Giant Cell Tumor is the most frequent primary tumor of the patella, although patellar tumors are rare.
Classic radiographic findings include an expansile osteolytic lesion, cortical thinning, fine septations, and no periosteal reaction.
MRI defines soft-tissue extension and local staging, whereas CT best depicts cortical destruction.
CT-guided biopsy is essential before definitive treatment in aggressive bone lesions.
Denosumab combined with surgery can preserve function, but long-term surveillance remains necessary because recurrence may occur.

References

Chakarun CJ, et al. Giant cell tumor of bone: Review, mimics, and new developments in treatment. Radiographics. 2013. DOI: 10.1148/rg.331125089.
Song M, et al. Primary tumors of the patella. World Journal of Surgical Oncology. 2015. DOI: 10.1186/s12957-015-0576-2.
Mavrogenis AF, et al. Giant cell tumor of bone revisited. SICOT-J. 2017. DOI: 10.1051/sicotj/2017038.
Tsukamoto S, et al. Current concepts in the treatment of giant cell tumors of bone. Cancers. 2021. DOI: 10.3390/cancers13153647.
Singh AS, et al. Giant-cell tumor of bone: Treatment options and role of denosumab. Biologics. 2015. DOI: 10.2147/BTT.S67639.